Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference

Br J Haematol. 2018 Apr;181(1):145-148. doi: 10.1111/bjh.14526. Epub 2017 Jan 20.

Authors

Tullia Rushton¹, Inmaculada Aban², Daniel Young³, Thomas Howard¹, Lee Hilliard¹, Jeffrey Lebensburger¹

Affiliations

¹ Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
² Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
³ Radiology, Children's of Alabama, Birmingham, AL, USA.

PMID: 28107562
DOI: 10.1111/bjh.14526

No abstract available

Keywords: hydroxycarbamide; patient preference; sickle cell disease; silent infarct; stroke.

Publication types

Letter
Research Support, Non-U.S. Gov't
Review

MeSH terms

Cerebral Infarction / diagnostic imaging
Cerebral Infarction / drug therapy*
Cerebral Infarction / physiopathology
Female
Humans
Hydroxyurea / therapeutic use*
Male
Patient Preference*

Substances

Hydroxyurea